PUTHENPARAMPIL, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.894
AS - Asia 1.247
EU - Europa 1.013
SA - Sud America 340
AF - Africa 208
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 5.735
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.755
SG - Singapore 486
IT - Italia 375
BR - Brasile 257
CN - Cina 233
HK - Hong Kong 188
DE - Germania 104
VN - Vietnam 62
FI - Finlandia 59
NL - Olanda 58
PL - Polonia 52
GB - Regno Unito 46
SE - Svezia 44
TR - Turchia 41
RU - Federazione Russa 37
FR - Francia 31
AT - Austria 26
IN - India 23
CA - Canada 19
MX - Messico 17
AR - Argentina 15
AL - Albania 14
CH - Svizzera 14
JP - Giappone 14
UA - Ucraina 14
IR - Iran 13
KR - Corea 13
AE - Emirati Arabi Uniti 11
CI - Costa d'Avorio 11
IE - Irlanda 11
JO - Giordania 11
PA - Panama 11
AO - Angola 10
DO - Repubblica Dominicana 10
PY - Paraguay 10
UY - Uruguay 10
BF - Burkina Faso 9
BO - Bolivia 9
CG - Congo 9
CW - ???statistics.table.value.countryCode.CW??? 9
HN - Honduras 9
KE - Kenya 9
NI - Nicaragua 9
SA - Arabia Saudita 9
BD - Bangladesh 8
CL - Cile 8
CO - Colombia 8
EC - Ecuador 8
IS - Islanda 8
KZ - Kazakistan 8
MA - Marocco 8
ML - Mali 8
RS - Serbia 8
VE - Venezuela 8
AM - Armenia 7
BE - Belgio 7
BG - Bulgaria 7
CY - Cipro 7
ES - Italia 7
ID - Indonesia 7
IQ - Iraq 7
LB - Libano 7
LV - Lettonia 7
MZ - Mozambico 7
NG - Nigeria 7
TH - Thailandia 7
TN - Tunisia 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
AD - Andorra 6
AF - Afghanistan, Repubblica islamica di 6
BY - Bielorussia 6
CM - Camerun 6
CR - Costa Rica 6
CU - Cuba 6
CV - Capo Verde 6
GN - Guinea 6
GT - Guatemala 6
HU - Ungheria 6
JM - Giamaica 6
KG - Kirghizistan 6
LY - Libia 6
ME - Montenegro 6
NC - Nuova Caledonia 6
PR - Porto Rico 6
PT - Portogallo 6
SI - Slovenia 6
SO - Somalia 6
CD - Congo 5
DJ - Gibuti 5
DK - Danimarca 5
GE - Georgia 5
IL - Israele 5
KH - Cambogia 5
LU - Lussemburgo 5
MG - Madagascar 5
MW - Malawi 5
NA - Namibia 5
NZ - Nuova Zelanda 5
PE - Perù 5
Totale 5.536
Salva come PNG Salva come JPEG
Città #
Ashburn 397
Fairfield 375
Singapore 316
Woodbridge 210
Hong Kong 182
Chandler 177
Cambridge 145
Santa Clara 138
Houston 129
Seattle 116
Wilmington 111
Ann Arbor 100
Beijing 68
Boardman 64
Padova 64
Los Angeles 47
Munich 42
Bytom 37
San Diego 36
Milan 35
Princeton 31
Istanbul 30
Medford 29
Rome 29
Hefei 25
Buffalo 23
Des Moines 21
Helsinki 21
Nuremberg 21
Turku 20
Ho Chi Minh City 18
Roxbury 18
London 17
São Paulo 17
New York 16
Dong Ket 15
Norwalk 15
The Dalles 14
Jacksonville 13
Chicago 12
Vienna 12
Abidjan 11
Hanoi 11
Panama City 11
Amman 10
Brooklyn 10
Cagliari 10
Montevideo 10
Nanjing 10
Padua 10
Santo Domingo 10
Tirana 10
Tokyo 10
Warsaw 10
Dublin 9
Lappeenranta 9
Luanda 9
Managua 9
Nairobi 9
Redondo Beach 9
Bamako 8
Boston 8
Nanchang 8
Ouagadougou 8
San Francisco 8
Seoul 8
Turin 8
Willemstad 8
Porto Alegre 7
Reykjavik 7
Riga 7
Rio de Janeiro 7
Tashkent 7
Villafranca Padovana 7
Zurich 7
Abu Dhabi 6
Andorra la Vella 6
Bishkek 6
Brazzaville 6
Conakry 6
Grignasco 6
Guangzhou 6
Guarulhos 6
Havana 6
Maputo 6
Moscow 6
Nicosia 6
Noumea 6
Praia 6
Toronto 6
Vicenza 6
Yerevan 6
Amsterdam 5
Bari 5
Belgrade 5
Douala 5
Guatemala City 5
Harare 5
Johannesburg 5
Kabul 5
Totale 3.648
Salva come PNG Salva come JPEG
Nome #
Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study 277
BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset 188
Cortical relapses in multiple sclerosis 171
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset 170
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: A common, transient and clinically silent phenomenon 163
Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease 157
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy 157
Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination 156
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset 153
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. 149
Acute simultaneous development of brain tumour–like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis 145
BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset 143
Hyperreflective Foci in the Retina of Active Relapse-Onset Multiple Sclerosis 140
Cortical lesions and cognitive impairment in multiple sclerosis. 132
Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies 132
Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands 125
Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis 123
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy 122
A new T2 lesion in a patient with the clinically isolated syndrome does not necessarily imply a conversion to multiple sclerosis 119
Increased incidence of multiple sclerosis in the Veneto region, Italy. 118
D-KEFS ST failure identifies multiple sclerosis patients with worse objective and self-perceived physical and cognitive disability 117
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis 116
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis 109
Neuropsychological awareness in pediatrics (NAP): Proposal of a new cognitive self-report questionnaire for pediatric multiple sclerosis patients 105
Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965-2018 102
Validation of SMAC: normative data in the Italian population 99
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient 96
Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis 90
Association of Multiple Sclerosis with PM 2.5 levels. Further evidence from the highly polluted area of Padua Province, Italy 88
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 84
Blood biomarkers for Alzheimer’s disease with the Lumipulse automated platform: Age-effect and clinical value interpretation 82
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis 81
Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis 80
Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection 79
Profili clinici nella Sclerosi Multipla: riserva cognitiva e compromissione motoria lungo il decorso della malattia. 77
Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid 76
Trans-synaptic degeneration in the optic pathway: Exploring the role of lateral geniculate nucleus in early stages of relapsing-remitting multiple sclerosis 74
Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis 70
Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment along Disease Duration 66
Hyper-reflective foci changes in RRMS under natalizumab therapy 65
Sars-CoV2 infection in pregnant women with multiple sclerosis 63
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review 61
High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple Sclerosis 59
Case Report: Para-infectious cranial nerve palsy after bacterial meningitis 59
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis 58
A comparison of natalizumab's effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients. 57
Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease 56
A comparison of natalizumab’s effects on SDMT between pediatric-onset and adult-onset multiple sclerosis patients 54
Sexual Dysfunction in Multiple Sclerosis: The Role of Executive Function 53
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis 49
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders? 49
Case report: Breaking CNS immuno-privilege: TNFα-inhibitor triggers aseptic meningitis in a patient with rheumatoid arthritis 45
The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers 45
Characterization of children with early onset pediatric multiple sclerosis 44
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS 43
Relapsing tumefactive demyelination lesions: A unique, distinct inflammatory brain pathology 42
null 42
Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis 41
Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis 40
Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors 35
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 30
Encephalopathy as unique manifestation of Sjogren's syndrome: Expanding the spectrum of steroid-responsive encephalopathy 21
Totale 5.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.108
article - articoli 21.643
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.751
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021414 0 0 23 28 8 10 12 37 29 132 52 83
2021/2022428 13 14 45 33 31 53 20 46 17 30 33 93
2022/2023418 54 39 19 45 55 55 13 33 61 13 20 11
2023/2024398 12 43 47 37 36 48 31 24 14 24 39 43
2024/20251.781 19 104 63 87 241 45 98 183 134 95 287 425
2025/20261.500 426 464 610 0 0 0 0 0 0 0 0 0
Totale 5.842